Abstract

Cross-sectional imaging shows a limited diagnostic accuracy for the histological discrimination of small renal masses (SRM). In this scenario, a renal tumor biopsy is a safe, feasible and effective diagnostic tool that can guide treatment strategy by providing the histological characterization of a SRM. Although nephron-sparing surgery is still considered the gold standard treatment for patients with SRM, more and more evidence suggests that active surveillance (AS) is a reasonable alternative option, especially in old and comorbid patients. Indeed, owing to the relatively slow growth and favorable biology of SRM, AS followed up by, if necessary, a delayed intervention provides an optimal oncological outcome with low rates of systemic progression or death.

Highlights

  • Kidney cancer is one of the few tumors that is only treated if there is a radiological probability of malignancy

  • A percutaneous renal tumor biopsy (RTB) has emerged as a promising diagnostic tool that may help in the clinical decision-making process by distinguishing benign from malignant radiological inconclusive renal lesions, and may be considered suitable for patients who are candidates for either active surveillance or nephron-sparing treatments[1,2,3]

  • Tissue sampling can be realized with fine needle aspiration (FNA) and/or core biopsy (CB)[1,4]

Read more

Summary

Introduction

Kidney cancer is one of the few tumors that is only treated if there is a radiological probability of malignancy. This concern is related to the limited diagnostic accuracy of computed tomography and magnetic resonance imaging in the histologic characterization of small renal masses (SRM)[1]. A percutaneous renal tumor biopsy (RTB) has emerged as a promising diagnostic tool that may help in the clinical decision-making process by distinguishing benign from malignant radiological inconclusive renal lesions, and may be considered suitable for patients who are candidates for either active surveillance or nephron-sparing treatments[1,2,3].

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.